TBPH Q4 2020 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$716M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M-36.5% YoY

Gross Profit

-$46M-247.9% margin

Operating Income

-$76M-408.4% margin

Net Income

-$58M-312.0% margin

EPS (Diluted)

$-0.92

QoQ Revenue Growth

+2.6%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$66M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$469M

Total Liabilities

$773M

Stockholders' Equity

-$304M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$29M	-36.5%
Gross Profit	-$46M	$29M	-257.4%
Operating Income	-$76M	-$71M	-8.4%
Net Income	-$58M	-$66M	+10.9%

Revenue Segments

Co Promote Agreement

$12M62%

Collaborative Arrangement Revenue

$7M38%